MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
1831.03%
Quick Ratio
1831.03%
Cash Ratio
882.55%
Debt to Asset Ratio
14.77%
Unit: Thousand (K) dollars
Assets Breakdown
    • Marketable securities, current
    • Cash and cash equivalents
    • Marketable securities, non-curre...
    • Others
Liabilities Breakdown
    • Additional paid-in-capital
    • Accumulated deficit
    • Term loan, non-current
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
202,643
198,766
189,247
316,773
Marketable securities, current
208,444
153,616
152,670
67,162
Accounts receivable
-
20,000
-
-
Prepaid expenses and other current assets
9,336
7,397
7,800
7,367
Total current assets
420,423
379,779
349,717
391,302
Total property and equipment, gross
-
-
24,255
-
Accumulated depreciation
-
-
19,211
-
Property and equipment, net
4,391
4,682
5,044
5,538
Restricted cash
1,088
1,088
1,088
1,089
Marketable securities, non-current
83,821
10,556
18,114
-
Operating lease right-of-use asset
18,442
19,285
20,116
20,920
Other assets
3,460
4,320
3,048
3,209
Total assets
531,625
419,710
397,127
422,058
Accounts payable
2,212
4,013
1,794
2,918
Accrued expenses and other current liabilities
15,866
12,385
15,967
14,430
Operating lease liabilities, current
4,883
4,838
4,795
4,764
Total current liabilities
22,961
21,236
22,556
22,112
Operating lease liabilities, net of current portion
16,580
17,552
18,511
19,419
2026
-
0
-
-
2027
-
0
-
-
2028
-
0
-
-
2029
-
0
-
-
2030
-
33,602
-
-
2031
-
6,398
-
-
Total future principal payments
-
40,000
-
-
Add end of term charge
-
2,580
-
-
Less unamortized discount and issuance costs
-
-3,747
-
-
Less current portion of term loan
-
0
-
-
Term loan, non-current
38,960
38,833
-
-
Other liabilities, non-current
-
388
1,094
1,091
Total liabilities
78,501
78,009
42,161
42,622
Common stock, 0.001 par value 500,000,000 shares authorized as of june 30, 2026 and december 31, 2025 55,504,574 and 49,335,551 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively 10,372 shares subject to repurchase as of june 30, 2026 and december 31, 2025
56
50
49
48
Additional paid-in-capital
1,011,985
855,541
844,354
834,298
Accumulated other comprehensive (loss) income
-435
-135
110
69
Accumulated deficit
-558,482
-513,755
-489,547
-454,979
Total stockholders' equity
453,124
341,701
354,966
379,436
Total liabilities and stockholders' equity
531,625
419,710
397,127
422,058
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities,current$208,444K Cash and cashequivalents$202,643K (-23.40%↓ Y/Y)Prepaid expenses andother current assets$9,336K (41.26%↑ Y/Y)Total current assets$420,423K (55.05%↑ Y/Y)Marketable securities,non-current$83,821K Operating leaseright-of-use asset$18,442K (-15.04%↓ Y/Y)Property and equipment,net$4,391K (-26.89%↓ Y/Y)Other assets$3,460K (-3.00%↓ Y/Y)Restricted cash$1,088K (-0.09%↓ Y/Y)Total assets$531,625K (75.15%↑ Y/Y)Total liabilities andstockholders' equity$531,625K (75.15%↑ Y/Y)Total stockholders'equity$453,124K (72.79%↑ Y/Y)Total liabilities$78,501K (90.16%↑ Y/Y)Accumulated deficit-$558,482K (-31.44%↓ Y/Y)Accumulated othercomprehensive (loss) income-$435K Additionalpaid-in-capital$1,011,985K (47.29%↑ Y/Y)Term loan,non-current$38,960K Total currentliabilities$22,961K (15.38%↑ Y/Y)Operating leaseliabilities, net of current...$16,580K (-18.29%↓ Y/Y)Common stock, 0.001 parvalue 500,000,000...$56K (27.27%↑ Y/Y)Accrued expenses andother current...$15,866K (37.77%↑ Y/Y)Operating leaseliabilities, current$4,883K (3.50%↑ Y/Y)Accounts payable$2,212K (-39.66%↓ Y/Y)

Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics, Inc. (MAZE)